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Abstract
Background—In a previously reported CoFAR study, 55 subjects with egg allergy underwent 
randomized, placebo-controlled egg oral immunotherapy (eOIT). Active treatment induced 
desensitization in most and sustained unresponsiveness (SU) in a smaller subset. We hypothesized 
that component-resolved analysis of IgE, IgG4, IgA, IgA1, and IgA2 may identify potential 
biomarkers of SU in OIT subjects.
Methods—Longitudinal samples for 51 egg-allergic subjects (37 active, 14 placebo) were 
available. Egg white- (EW), ovalbumin- (OVA), and ovomucoid (OVM)-specific levels of IgA, 
IgA1, and IgA2 were quantified by ELISA. IgE and IgG4 to these antigens were quantified using 
ImmunoCAP®. Clinical responders achieved SU to egg; all others were considered non-
responders. Between-group comparisons were made amongst active and placebo, as well as 
responders and non-responders.
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Results—No placebo subjects achieved responder status. Through month 48, among the 37 
active subjects, baseline IgE-OVM was lower in responders (median 3.97 kU/L, n=19) than non-
responders (10.9 kU/L, n=18, p=0.010). Logistic regression analysis revealed lower baseline IgE-
EW (p = 0.038), IgE-OVM (p = 0.032) and a higher IgG4:IgE-OVM ratio (p=0.013) were 
associated with clinical response. Relative increases in IgG4-EW, IgA-EW and IgA2-EW were 
greater in responders (p= 0.024, 0.024, 0.029, respectively). Ratios of IgG4:IgE, IgA:IgE, 
IgA2:IgE for EW and IgA:IgE for OVA were significantly elevated among responders (p = 0.004, 
0.009, 0.028, 0.008, respectively).
Conclusions—Increased IgG4-EW, IgA-EW and IgA2-EW during eOIT are associated with 
clinical response to eOIT. Lower pre-treatment IgE-EW and IgE-OVM are also associated with 
SU. Future studies are needed to evaluate and validate these potential biomarkers.
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Introduction
Food allergy affects approximately 8% of children in the United States (1). Young children 
are disproportionately affected, with prevalence estimates exceeding 10% in some regions 
(2). Epidemiologic studies suggest that up to 2.5% of all children are allergic to hen's egg 
and it is the most common food sensitization at one year of life (3-5). Egg allergy resolves in 
about half of children by 6 years and two-thirds of children by age 16 (6, 7). However, egg 
allergy is a risk factor for the development of other food allergies, atopic dermatitis and 
asthma (8-10). In addition, difficulty associated with egg avoidance has generated intense 
interest in investigational therapies.
The Consortium of Food Allergy Research (CoFAR) investigators previously reported the 
results of a multicenter, double-blind, randomized, placebo-controlled trial investigating the 
safety and effectiveness of egg oral immunotherapy (eOIT) in children (11). After 10 months 
of treatment, we demonstrated that 55% of egg-allergic subjects were desensitized; whereas, 
none of the subjects on placebo passed an oral food challenge (OFC). At 22 months, the rate 
of desensitization among subjects receiving eOIT increased to 75%. Importantly, after 
discontinuation of eOIT for 4-6 weeks, 28% of the subjects in the OIT group tolerated an 
egg OFC. These individuals were considered to have sustained unresponsiveness (SU). 
Subjects without SU at 22 months were maintained on OIT with subsequent assessments at 
36 and 48 months, demonstrating an increase in the proportion of subjects with SU to 50% 
at month 48 (12).
Limited mechanistic data have been published from large, prospective, controlled, OIT trials 
to identify predictors and biomarkers associated with SU. The purpose of this study was to 
determine whether we could detect such biomarkers in the serum of children undergoing 
eOIT. Because allergenic foods are complex, heterogeneous substances consisting of 
multiple proteins, component resolved diagnostic (CRD) tools have been developed to more 
precisely identify the antigenic targets of IgE. For example, the heat-stable, component 
protein ovomucoid has been identified as the dominant egg white allergen (13). Some 
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evidence suggests allergen-specific (sIgE) testing for ovomucoid may discriminate egg-
tolerant from egg-allergic subjects (14) and, we hypothesized that those with lower 
ovomucoid-specific IgE are more likely to respond to eOIT.
In addition to sIgE, other immunoglobulin classes and subclasses are likely important for the 
development of SU. Egg-specific IgG4 levels tend to rise in subjects undergoing eOIT (11); 
moreover, IgE:IgG4 ratios have been used to predict clinical reactivity to baked egg (15). 
IgA and its subtypes, IgA1 and IgA2, may also play a role as increases in antigen-specific 
IgA are seen in the saliva of subjects who respond favorably to peanut sublingual 
immunotherapy (SLIT) (16). Similarly, increases in antigen-specific IgA2 have been 
observed in the serum of subjects receiving subcutaneous immunotherapy (SCIT) for grass 
pollen allergy (17). Given these observations, we hypothesized that component resolved 
analysis of the serologic parameters IgA, IgA1, IgA2, IgE, and IgG4 would identify 
potential biomarkers of SU.
Methods
Clinical Protocol Summary
The clinical study protocol and results of the first 24 months of the clinical trial 
(NCT00461097) have been described previously (11). Fig E1 (Online Repository) is a 
CONSORT flow diagram detailing outcomes of subjects through month 48 (12). Briefly, 
egg-allergic subjects receiving eOIT, continued open label treatment up to 48 months or until 
they achieved SU. All subjects continuing eOIT in the active treatment arm underwent a 10g 
OFC at 36 months and 48 months to monitor for desensitization. If a child passed the 
desensitization OFC, a subsequent OFC paired with a 10 g open egg feeding was performed 
4-6 weeks later to assess for SU. Subjects who achieved SU were allowed to incorporate egg 
into the diet and were followed until the end of the study. The primary clinical efficacy 
outcome of the study was the percentage of subjects achieving SU by 48 months.
Subjects
Forty subjects were originally randomized to eOIT; 20 achieved SU and were classified as 
clinical responders (n=19 with samples available for analysis). All others in the active 
treatment arm were classified as non-responders (n=18 with samples available for analysis). 
Longitudinal blood samples were collected over a 4-year period at 3, 10, 22, 36 and 48 
months. Plasma samples were kept frozen at -80°C until analysis and assigned a unique 
identifier. Laboratory personnel were blinded during the analysis until the data were 
finalized.
IgA Measurement
Egg white (EW)-, ovalbumin (OVA)-, and ovomucoid (OVM)-specific IgA, IgA1 and IgA2 
were measured by ELISA. OVA (albumin from chicken egg white; Grade V, >98% pure 
based on SDS-PAGE) and OVM (trypsin inhibitor from chicken egg white; Type III-O, free 
of ovoinhibitor, >99% pure based on SDS-PAGE) were purchased from Sigma-Aldrich. Egg 
proteins were coated on Immulon 4HBX microtiter plates (Thermo Fisher Scientific) at 
concentrations of 20 (EW), 5 (OVA), and 5 (OVM) μg/ml for one hour at 37°C. Standard 
Wright et al. Page 3













curve wells were coated with mouse anti-human IgA1/IgA2 capture antibody (BD, diluted 
1:250). Plates were then blocked with a PBS solution containing 0.05% Tween-20 and 2% 
BSA for one hour at 37°C. Diluted plasma samples were added and left to bind egg antigens 
overnight at 4°C. Detection was performed with the following antibodies diluted in blocking 
solution: goat anti-human IgA-HRP antibody (Southern Biotech, diluted 1:1000); mouse 
anti-human IgA1-HRP antibody (Southern Biotech, diluted 1:1000); mouse anti-human 
IgA2-HRP antibody (Southern Biotech, diluted 1:1500). The plates were then incubated at 
37°C for one hour.
The detection system was developed with TMB substrate (KPL) for 10 minutes, acidified 
with a TMB stop solution (KPL); and then read on an ELISA plate reader to determine 
optical density (O.D.). Optical densities were compared to a standard curve and converted to 
weight per volume concentrations. A vast majority of the samples were diluted 1:10 in 
blocking solution. Samples out of range of the standard curve were diluted further until an 
O.D. < 4 was obtained.
IgE and IgG4 Measurement
EW-, OVA- and OVM-specific IgE and IgG4 were measured in plasma using the 
ImmunoCAP 100 instrument (Phadia AB) according to the manufacturer's instructions.
Statistical Analysis
Subjects were grouped according to treatment arm and responder status. Wilcoxon ranked-
sum test (unadjusted for multiplicity of tests) was used to compare median immunoglobulin 
measurements between non-responders and responders at baseline. Correlations at baseline 
were determined by generating Spearman's rank correlation coefficients. Logistic regression 
analysis was used to identify predictors of clinical responses to eOIT. Values were log-
transformed given highly skewed distributions. Mean values for each serologic parameter 
and log-transformed ratios of IgG4:IgE, IgA:IgE, IgA1:IgE and IgA2:IgE for EW, OVA, and 
OVM were compared among responders and non-responders (and placebo where noted) 
using a repeated-measurement analysis with an unstructured covariance matrix. Endpoint-to-
baseline ratios were compared using the same repeated-measurement analysis. Interactions 
between visit and responder status were considered. If significant, the interaction p-value 
was reported. If not, the interaction term was removed and the main effect p-value was 
considered. Given the exploratory nature of the analysis, adjustment for multiple 
comparisons was not performed and a p-value of <0.05 was considered significant.
Results
Baseline comparisons of groups according to clinical outcomes
We examined baseline serologic parameters to identify possible predictors of SU. 
Responders had lower median baseline IgE levels to all antigens measured. Between-group 
comparisons of untransformed baseline values demonstrated that the median baseline IgE-
OVM values were significantly greater in non-responders than responders (10.9 vs. 3.97 
kU/L, p=0.011) For IgE-EW, this difference did not reach statistical significance (20.03 vs. 
9.59 kU/L p = .052). Despite the general trend for responders to have lower IgE levels, these 
Wright et al. Page 4













parameters had large standard deviations (Table 1 and Figure 1). In addition to having 
greater baseline IgE levels, non-responders were distributed over a much wider range. IgA 
and IgA1 varied more among responders, whereas this pattern was reversed for IgA2.
Logistic regression models using log-adjusted baseline values suggest lower baseline IgE-
EW (p = 0.038 AUC 0.69 (0.51,0.86 95% CI)), IgE-OVM (p = 0.032, AUC 0.74 (0.58, 0.91 
95% CI)), and higher IgG4:IgE for OVM (p = 0.013, AUC 0.70 (0.51, 0.89 95% CI)) were 
potential predictors of clinical response. Odds ratios for response per log increase of IgE-
EW and IgE-OVM were 0.178 (95%CI 0.032, 0.906) and 0.28 (95%CI 0.088, 0.895), 
respectively. No regression models had multiple significant parameters and no other 
differences in baseline serologic parameters were significant.
To better characterize the relationships between baseline immunoglobulin measurements, we 
examined Spearman's rank correlation coefficients (Table 2). This allowed us to determine 
correlations between EW and is component proteins for IgE, IgG4, IgA, IgA1 and IgA2. In 
addition, we were able to define correlations between specific immunoglobulin classes/
subclasses. Positive correlations (rs>0.50) existed between EW-, OVA- and OVM-specific 
levels of each immunoglobulin class/subclass. We also found positive correlations between 
IgG4 and IgA/IgA1 to all antigens.
Immunoglobulin trends during OIT
We measured the longitudinal production of IgE, IgG4, IgA, IgA1 and IgA2 to EW, OVA, 
and OVM to determine whether specific patterns emerged distinguishing responders from 
non-responders. Plasma samples from subjects receiving placebo were only available during 
the first 24 months of the study. First, we examined trends between groups to guide the 
analysis (Figure 2). Overall, we observed similar trends when these immunoglobulins were 
measured to EW or its component antigens, OVA and OVM. Generally, IgE increased 
among subjects on OIT during the first three months of the study. Declines in IgE were 
subsequently noted in these subjects; whereas, IgE for subjects on placebo remained 
constant. The IgE differences between the active treatment and placebo groups were 
statistically significant for all antigens (interaction p: IgE-EW=0.0001, IgE-OVA=0.005, 
IgE-OVM=0.0004) with significant interactions indicating differences between groups were 
not constant over time.
In contrast, IgG4 levels increased in subjects receiving active treatment in comparison to the 
placebo group (interaction p<0.0001 for all antigens). These increases were most 
pronounced among responders. IgG4 levels for all antigens rose sharply at 3 months and 
levels continued to increase until approximately 36 months. Parallel to IgG4, increases in 
IgA (interaction p: IgA-EW=0.004, IgA-OVA=0.031, IgA-OVM=0.008), IgA1 (interaction 
p: IgA1-EW=0.005, IgA1-OVA=0.010, IgA1-OVM=0.013) and IgA2 (interaction p: IgA2-
EW=0.047, IgA2-OVA=0.023, IgA2-OVM=0.001) were observed in subjects receiving OIT. 
These increases were not observed in subjects on placebo. Responders demonstrated 
sustained increases in IgA, IgA1, and IgA2 to all antigens. Interestingly, IgA1-OVM at 36 
and 48 months showed a large degree of separation between responders and non-responders. 
Although increases in IgA and its subtypes mirrored increases in IgG4, differences between 
responders and non-responders were not as pronounced.
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IgG4, IgA and IgA2 differ between responders and non-responders during OIT
We noted a large degree of variation in the baseline immunoglobulin measurements of 
subjects (Table 1). We considered endpoint-to-baseline ratios of log-transformed 
immunoglobulin measurements for each time point. This allowed us to compare relative 
increases for each of the serologic parameters (Figure 3). Repeated measurement analysis of 
IgG4, IgA, and IgA2 to EW revealed significant differences between responders and non-
responders. Greater increases were observed among responders for IgG4-EW (interaction p= 
0.024), IgA-EW (interaction p=0.024), IgA2-EW (main effect p=0.029) and IgG4-OVM 
(interaction p = 0.025). Combining endpoint to baseline ratios for IgG4-EW and IgA-EW 
had an additive effect in discriminating responders and non-responders (IgG4-EW+IgA-EW, 
interaction p < 0.001). Statistically significant interactions indicate that the difference 
between responders and non-responders is not constant over time.
Ratios of IgG4, IgA and IgA2 to IgE distinguish responders and non-responders
To further investigate differences between responders and non-responders receiving active 
treatment, we performed repeated measurement analysis of ratios of IgG4, IgA, IgA1, and 
IgA2 to IgE for EW, OVA and OVM (Figure 4). All ratios were increased among responders 
(main effect p < 0.05). Significant time by responder group interactions were noted for the 
following ratios: IgG4:IgE-EW (interaction p = 0.004), IgA:IgE-EW (interaction p = 0.009), 
IgA2:IgE-EW (interaction p = 0.028), IgA:IgE-OVA (interaction p = 0.008), with significant 
interactions indicating differences between groups were not constant over time. To assess the 
sensitivity of the results, samples for subjects who had been off treatment for greater than 6 
months were removed (n=15) and the models were refit. IgG4 and IgA1 results were 
consistent with the full analysis while IgA and IgA2 ratios were typically not significant at 
the 0.05 level after removal of the samples. It is unclear, however, whether the change in 
significance was due an exposure effect or the loss of samples from the analysis.
Discussion
Over the last decade, researchers have performed clinical trials investigating the safety and 
efficacy of OIT as a treatment modality to desensitize children allergic to common food 
allergens (18). Once desensitized, an allergic individual can ingest relatively large quantities 
of the allergenic food if regular maintenance dosing is continued (11, 19, 20); 
notwithstanding, the permanence of immunologic changes induced by OIT remains in 
question (21, 22). While OIT is a promising proactive therapeutic approach for food 
allergies, it is critical to define markers to distinguish subjects who have developed SU from 
those only transiently desensitized. Our findings suggest that subjects who develop SU have 
lower IgE-OVM levels, and increased IgG4:IgE-OVM ratios at baseline During OIT, they 
show greater relative increases in IgG4, IgA and IgA2 during OIT and have increased ratios 
of IgG4, IgA and IgA2 to IgE. These parameters may distinguish individuals who respond 
favorably to OIT and provide unique insights into its immunoglobulin-mediated 
mechanisms.
The immunologic changes induced by OIT have been described in several studies (16, 
23-27) and generally include: (1) an initial rise in specific-IgE followed by a decrease below 
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baseline levels (26); (2) a decrease in skin prick test wheal diameter; (3) increases in 
antigen-specific IgG4; (4) decreased ex vivo basophil activation upon antigenic stimulation; 
(5) alterations in T cell responses such as increased regulatory T cells and decreased Th2 
cytokine production. Recently, Gorelik et al (27) reported that baseline basophil CD63 
expression, histamine release and IL-4 production significantly correlate with SU in subjects 
undergoing OIT. While these changes are informative and provide some insight into the 
mechanisms of OIT, specific biomarkers associated with SU have not been rigorously 
examined in large, controlled OIT trials. We previously assessed egg-specific IgE and IgG4 
and found that, at 10 months, SU correlated with egg-specific IgG4 levels but not egg-
specific IgE (11). In the present study, we hypothesized that component-resolved analysis of 
IgE, IgG4, IgA, IgA1, and IgA2 would identify possible predictors of SU at baseline or 
changes in these serologic markers during the course of eOIT indicative of SU.
The increase in SU from 28% at 22 months to 50% at 48 months suggests that longer 
duration of treatment is valuable for some patients. In our study, we found that lower 
baseline log IgE-EW and log IgE-OVM were associated with SU at Year 4. No significant 
differences were found between groups for IgG4, IgA, IgA1, or IgA2 at baseline. Vickery et 
al. (22) reported similarly that IgE levels to peanut and the major allergens, Ara h 1 and Ara 
h 2, were lower at baseline in a subset of subjects that developed SU after peanut OIT. 
Longitudinally, responders tended to have lower IgE values to EW, OVA and OVM in 
comparison to non-responders (Figure 2), although statistically significant differences were 
not observed.
Despite reaching statistical significance (p< 0.05), we did not derive predictive thresholds 
for baseline IgE-EW or IgE-OVM as the large variability of baseline values and low AUCs 
(IgE-EW= 0.69 and IgE-OVM= 0.74) from the logistic regression model indicated limited 
predictive value. Importantly, some subjects with low IgE did not develop SU at 48 months 
(Figure 1). Utilizing epitope arrays with peptides from ovomucoid to determine levels of IgE 
binding to various peptides may be a more definitive approach. Bioinformatics analysis of 
epitope recognition patterns has successfully distinguished subjects who are sensitized, but 
tolerant, from those who are peanut-allergic (28).
According to our results, component testing may enhance our predictive ability to identify 
OIT responders. For example, IgE-OVM was a slightly better predictor of SU than IgE-EW 
at baseline and was significantly elevated in responders when compared to non-responders 
(Figure 1). Moreover, the IgG4:IgE-OVM ratio was significantly higher among responders; 
whereas, this was not true for EW or OVA. Nonetheless, we generally observed that 
immunoglobulin levels to EW and its component proteins (OVA, OVM) correlated strongly 
at baseline (Table 2) and similar trends during eOIT were observed across antigens for IgE, 
IgG4, IgA, IgA and IgA2 (Figure 2). Recent studies of both egg (29) and peanut (22) OIT 
suggest that baseline IgE to whole food protein are better predictors of response to OIT.
We corroborate previous findings that antigen-specific IgG4 increases in subjects receiving 
OIT in comparison to placebo. IgG4 has functional capacity to inhibit IgE-mediated immune 
function. For example, peanut-specific IgG inhibits antigen-IgE-FcεRII complex formation 
in a facilitated antigen binding (FAB) inhibition assay (22, 23). More recently, IgG and IgG4 
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in plasma from subjects on OIT have been shown to inhibit IgE-mediated basophil activation 
(30). Despite this, reports from previous OIT trials have not found correlations of IgG4 
levels with clinical outcomes of SU (11, 22, 26). Given wide variation in subjects' 
immunoglobulin responses to OIT, we demonstrate that relative, rather than absolute, 
increases in IgG4 distinguish responders from non-responders. These increases may reflect 
changes in T cell responses driving IgG4 production, such as increased IL-10 secretion, 
possibly from regulatory T cells (24). IL-10-secreting B cells (regulatory B cells) may also 
play a role (31). Future studies should compare the inhibitory function of IgG4 in the plasma 
of responders and non-responders, providing an opportunity to correlate the functional 
effects of IgG4 on effector cell activity with clinical outcomes.
As the most abundant immunoglobulin in the human body, IgA is well known for its role in 
mucosal immunity and is particularly important for antigen exclusion in the gastrointestinal 
tract (32). Increases in serum IgA2-EW have been associated with development of natural 
tolerance in egg allergy (33) and antigen-specific serum IgA has been shown to increase in 
SCIT with aeroallergens (17). We found that similar to SCIT, EW-, OVA- and OVM-specific 
IgA, IgA1 and IgA2 increased with OIT compared to placebo. Interestingly, we noted 
significant differences between responders and non-responders in the relative increases of 
IgA-EW and IgA2-EW, but not IgA1-EW (Figure 3). The fact that relative increases in IgA1 
were not significantly associated with responder status is intriguing and may be because 
serum IgA2 better correlates with IgA production at mucosal surfaces. Pilette et al. (17) 
demonstrated that antigen-specific IgA2 levels increased approximately 5-fold during 
aeroallergen SCIT whereas specific-IgA1 increased to a far lesser extent. This may be due to 
preferential changes in class switch recombination in IgE-producing B cells given the IgA2 
(α2) H chain gene, in contrast to IgA1 (α1), is situated downstream of the IgE (ε) gene. 
Indeed, IgA2 levels in serum correlate with increases in TGF-beta from nasal biopsies (17, 
21), indicating that systemic measurement of IgA2 may reflect changes in local 
compartments. Mucosal, antigen-specific IgA concentrations correlate with clinical 
outcomes, as increases in salivary IgA are greater in peanut allergic subjects achieving 
desensitization after 12 months of peanut SLIT (16).
While serum IgA2 may more accurately reflect local IgA concentrations, serum IgA itself 
may play an important role in preventing food-induced reactions. In mouse models of egg 
allergy, serum IgA, not secretory IgA in the gut lumen, is essential in protecting mice from 
anaphylaxis after oral administration of egg (34). We found in the majority of responders 
that antigen-specific serum IgA, IgA1, and IgA2 production was elevated and sustained 
throughout 48 months. In contrast, the non-responders had initial increases, which tended to 
decrease by 48 months. Examining longitudinal trends, the absolute levels of IgA1-OVM 
remained elevated at 48 month in responders, but had returned to near-baseline levels in the 
non-responders by 36 months. A recent study by Dodev et al. (35) showed that antibodies of 
different classes with the same specificity, including IgA, inhibit allergen-dependent IgE 
activity. Consequently, we hypothesize sustained, elevated levels of IgA-EW, IgA1-OVM, 
and IgA2-EW may prevent reactions during OFC's. Future studies should examine antigen-
specific IgA levels in stool and saliva of subjects undergoing OIT to evaluate whether the 
systemic IgA increases we measured in plasma are correlated with local mucosal levels. 
Investigation of antigen-specific IgA secreting B-cell populations may also distinguish 
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responders from non-responders as our data suggest that EW-specific, IgA-secreting B cells 
may more readily undergo apoptosis.
In summary, we report for the first time that egg- and component-specific IgA, IgA1 and 
IgA2 levels in plasma increase during eOIT and that relative increases in IgG4, IgA and 
IgA2 to EW and OVM are greater in responders than in non-responders. Ratios of IgG4, IgA 
and IgA2 to IgE may be useful in determining clinical response to egg OIT. Together these 
findings suggest that these IgG4 and IgA may be functionally protective after OIT is 
stopped. Ultimately, detailed mechanistic studies that link together T cell phenotypes, 
immunoglobulin levels, and effector cell functions will be key to advancing the field of food 
allergy immunotherapy.
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Comparison of log transformed IgE-EW and IgE-OVM values between groups at baseline. 
Panel A depicts differences among groups for log IgE-EW. Panel B shows differences for 
log IgE-OVM. Statistical comparisons of baseline median values performed using exact 2-
sided Wilcoxon unadjusted for multiplicity of tests.
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Immunoglobulin trends for antigen-specific IgE, IgG4, IgA, IgA1, and IgA2 among groups. 
Responder status defined as passing a DBPCFC after at least 4 weeks off therapy at 22, 36 
or 48 months. Graphs show logarithmic mean and SEM for each immunoglobulin 
measurement. Horizontal axis depicts time in months during the clinical trial.
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Trends in endpoint-to-baseline log ratios between responders and non-responders. Graphs 
show logarithmic mean and SEM of endpoint-to-baseline ratios for serologic parameters 
with significant differences between responders and non-responders. Relative increases in 
the IgG4-EW (A), IgG4-OVM (B), IgA-EW (C), IgA2-EW (D), and the sum of IgG4-EW 
and IgA-EW (E) are depicted.
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Log ratios of IgA, IgA1, IgA2 and IgG4 to IgE for EW, OVA and OVM in responders versus 
non-responders. Graphs show logarithmic mean and SE for ratios with significant 
differences between responders and non-responders. Ratios of IgG4:IgE, IgA:IgE, IgA2:IgE 
to EW and IgA:IgE to OVA have significant time by responder group interactions.
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